State of New Jersey Common Pension Fund D Sells 14,402 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

State of New Jersey Common Pension Fund D decreased its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 35.4% during the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 26,313 shares of the medical equipment provider’s stock after selling 14,402 shares during the quarter. State of New Jersey Common Pension Fund D’s holdings in Lantheus were worth $2,113,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in the stock. Daiwa Securities Group Inc. acquired a new position in Lantheus in the 1st quarter valued at approximately $1,269,000. Clearbridge Investments LLC raised its stake in shares of Lantheus by 45.4% in the fourth quarter. Clearbridge Investments LLC now owns 538,782 shares of the medical equipment provider’s stock valued at $33,404,000 after purchasing an additional 168,114 shares in the last quarter. Nordea Investment Management AB lifted its position in Lantheus by 42.6% in the first quarter. Nordea Investment Management AB now owns 47,322 shares of the medical equipment provider’s stock worth $2,932,000 after purchasing an additional 14,147 shares during the period. Hancock Whitney Corp boosted its stake in Lantheus by 265.6% during the first quarter. Hancock Whitney Corp now owns 20,151 shares of the medical equipment provider’s stock worth $1,254,000 after buying an additional 14,639 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC bought a new stake in Lantheus in the 2nd quarter valued at $290,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Stock Performance

Shares of NASDAQ:LNTH opened at $110.05 on Friday. The business has a fifty day moving average of $105.51 and a 200-day moving average of $84.10. The company has a debt-to-equity ratio of 0.55, a quick ratio of 4.41 and a current ratio of 4.68. Lantheus Holdings, Inc. has a twelve month low of $50.20 and a twelve month high of $126.89. The firm has a market cap of $7.63 billion, a PE ratio of 16.80 and a beta of 0.50.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share for the quarter, missing the consensus estimate of $1.68 by ($0.07). Lantheus had a net margin of 29.80% and a return on equity of 48.36%. The company had revenue of $394.10 million during the quarter, compared to analyst estimates of $382.12 million. During the same quarter in the previous year, the business posted $1.40 EPS. The company’s revenue was up 22.5% compared to the same quarter last year. On average, equities research analysts predict that Lantheus Holdings, Inc. will post 5.99 EPS for the current fiscal year.

Insider Buying and Selling at Lantheus

In other news, CAO Andrea Sabens sold 341 shares of the business’s stock in a transaction on Monday, July 15th. The stock was sold at an average price of $123.15, for a total transaction of $41,994.15. Following the completion of the sale, the chief accounting officer now owns 62,216 shares in the company, valued at $7,661,900.40. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, CAO Andrea Sabens sold 341 shares of the stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $123.15, for a total value of $41,994.15. Following the transaction, the chief accounting officer now directly owns 62,216 shares in the company, valued at $7,661,900.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Gerard Ber sold 15,500 shares of the firm’s stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the completion of the transaction, the director now directly owns 21,221 shares in the company, valued at $2,047,402.08. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 40,852 shares of company stock worth $3,922,001. Insiders own 1.50% of the company’s stock.

Wall Street Analysts Forecast Growth

LNTH has been the subject of several recent research reports. Redburn Atlantic assumed coverage on shares of Lantheus in a research report on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 price target for the company. Leerink Partners increased their target price on Lantheus from $106.00 to $127.00 and gave the stock an “outperform” rating in a report on Thursday, July 11th. B. Riley boosted their price target on Lantheus from $105.00 to $146.00 and gave the company a “buy” rating in a research note on Thursday, July 25th. Truist Financial dropped their price objective on Lantheus from $141.00 to $135.00 and set a “buy” rating for the company in a research note on Thursday, August 1st. Finally, JMP Securities reduced their target price on shares of Lantheus from $130.00 to $125.00 and set a “market outperform” rating on the stock in a research note on Thursday, August 1st. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $126.00.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.